Gitnux/Report 2026

Lifescience Industry Statistics

307Statistics
108Sources
12Sections
1Visuals
48mRead
Lifescience Industry Statistics
Samuel NorbergWritten by Samuel Norberg·Fact-checked by Maya Johansson
Published
How this report is researched
01Editorial Scope

Before any source is gathered, an editor locks the question, what qualifies, and how the piece will be judged.

02Source Research

Search agents collect the source set and pull each data point out with its provenance attached.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 39 days

01 Industry overview

The lifescience industry at a glance

Life sciences is a large, innovation-led industry: global prescription pharmaceutical sales reached $1.53 trillion in 2024, while new therapies, AI-enabled devices and targeted acquisitions continue reshaping growth.

$1.53T[72]
Global pharma sales, 2024
5–8%[43]
Medicine spending CAGR to 2029
54.8%[72]
North America pharma share, 2024
46[59]
FDA novel drugs approved, 2025
Market size
The global prescription pharmaceutical market was worth an estimated €1.414 trillion, or $1.529 trillion, at ex-factory prices in 2024. In the United States, pharmaceutical sales were approximately $719 billion in 2024, according to SelectUSA.[72][97]
Forecast & CAGR
IQVIA forecasts global medicine spending to grow at a 5–8% CAGR through 2029 and reach approximately $2.4 trillion. Growth is expected to be supported by oncology, immunology, diabetes and obesity therapies, although medicine-use growth is projected to moderate.[43]
Market share & regions
North America accounted for 54.8% of global pharmaceutical sales in 2024, compared with 22.7% for Europe, 7.1% for China and 4.0% for Japan. The United States also represented 66.9% of sales for new medicines launched globally during 2019–2023.[72]
Segmentation
The industry spans pharmaceuticals and biopharmaceuticals, medical devices, diagnostics, research and development, laboratories, contract research and manufacturing, and distribution. In the United States, the biopharmaceutical cluster employed more than 321,000 people and the medical-device cluster more than 285,000 in the latest SelectUSA figures.[97][98]
Key players & concentration
The United States remains a major concentration of industry capabilities: California, Maine, Massachusetts, New Jersey and Utah have high employment shares and high employee concentration in biopharmaceuticals, while Arizona, California, Indiana, Minnesota and Utah are leading medical-device clusters. No single global concentration ratio covering the full life sciences industry was identified from a reliable source.[97]
Pricing
In Europe, an estimated 67.0% of the retail price of a medicine went to the manufacturer in 2023, while wholesalers received 10.5%, pharmacists 5.0% and the state through VAT and other taxes 17.5%. Pricing varies substantially by country because reimbursement, distribution margins and tax rates differ.[72]
Trends, drivers & challenges
Growth is being driven by personalized medicine, aging populations, chronic disease, AI, obesity therapies and advanced biologics. At the same time, the sector faces rising R&D costs, funding constraints, inflation, supply-chain complexity and regulatory uncertainty; U.S. FDA-authorized AI-enabled medical devices rose from six in 2015 to more than 250 in 2025.[97][12]
Consumer behavior & competition
Medicine use is expected to grow more slowly than spending: IQVIA projects global per-capita medicine use to rise at a 1.9% CAGR over the next five years, versus 2.7% unadjusted for population. Competition is increasingly centered on innovative therapies, while generics and biosimilars exert downward pressure after loss of exclusivity.[43][72]
M&A
Life sciences M&A reached 193 transactions worth $220 billion by the end of November 2025, according to Deloitte. In 2026, buyers are emphasizing targeted tuck-in acquisitions, late-stage assets, advanced biologics, metabolic disease, diagnostics, AI-enabled clinical services and manufacturing capabilities.[12]
Regulation
The FDA approved 46 novel drugs in 2025; 39, or 85%, were approved during the first review cycle, and 32, or 70%, were approved in the United States before any other country. Regulatory scrutiny, drug-price policy and evidence requirements remain important commercial factors across pharmaceuticals, devices and diagnostics.[59]
Latest news
The latest industry developments include a rebound in life sciences M&A, continued expansion beyond oncology into cardiology, metabolic disease and neuroscience, and accelerating use of AI in medical devices and drug development. Deloitte reported that 2025 M&A deal value surpassed 2024 levels, while SelectUSA reported more than 250 FDA-authorized AI-enabled medical devices in 2025.[12][97]

02 Ranking

Top 10 Companies in the Lifescience Industry

The leading companies in the lifescience industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 10, 2026 · Next review December 10, 2026

Verdict

Eli Lilly leads Gitnux's 2026 lifescience ranking with an Overall score of 9.6, with R&D at 20.5% of revenue and operating margin at 40.4%. Novo Nordisk is the highest-ranked pharmaceutical company at 9.1, with operating margin at 41.3% and R&D at 16.8% of revenue.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in innovative prescription drugs

    Eli Lilly

    US

    Ranked #1 · 9.6 · Innovative prescription drugs

    Why we picked it: Innovative pharmaceuticals and biotechnology, with diabetes, obesity, and oncology therapies and high R&D intensity.

    See in ranking ↓Visit lilly.com ↗

  2. Leader in diabetes and obesity medicines

    Novo Nordisk

    DK

    Ranked #2 · 9.1 · Diabetes and obesity medicines

    Why we picked it: Diabetes, obesity, and rare-disease medicines backed by high operating margin in its core segment.

    See in ranking ↓Visit novonordisk.com ↗

  3. Leader in pharmaceuticals and diagnostics

    Roche

    CH

    Ranked #3 · 9.0 · Pharmaceuticals and diagnostics

    Why we picked it: Pharmaceuticals and diagnostics combine oncology and other serious disease portfolios under one organization.

    See in ranking ↓Visit roche.com ↗

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the lifescience industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Eli Lilly

Innovative prescription drugs · US

9.6
2

Novo Nordisk

Diabetes and obesity medicines · DK

9.1
3

Roche

Pharmaceuticals and diagnostics · CH

9.0
4

Novartis

Innovative prescription drugs · CH

9.0
5

AstraZeneca

Innovative prescription drugs · GB

8.9
6

Amgen

Biotechnology and therapeutics · US

8.8
7

Medtronic

Medical devices and therapies · IE

8.8
8

Sanofi

Vaccines and biopharmaceuticals · FR

8.7
9

Thermo Fisher Scientific

Life-science tools and bioproduction · US

8.6
10

AbbVie

Biopharmaceuticals · US

8.2

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 10, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 10). Top 10 companies in the lifescience industry. In Lifescience Industry Statistics. Gitnux. https://gitnux.org/lifescience-industry-statistics/#top-companies

report visual · Comparison

Revenue of the largest lifescience companies

Roche leads with $69.5B in annual revenue (group level, converted to USD).

Roche$69.5B
Eli Lilly$65.2B
AstraZeneca$58.7B
Novartis$54.5B
Novo Nordisk$44.8B
Thermo Fisher Scientific$44.6B
source-verifiedroche.com · investor.lilly.com · astrazeneca.com · novartis.com · annualreport.novonordisk.com · ir.thermofisher.com2025

04 Statistics

Technology & Innovation

Adoption centers on analytics and automation, with 87% of life-sciences organizations integrating AI agents into workflows, products, or services in 2026.

AI in the lifescience industry

  • 61% of pharma and biotech respondents identified predictive analytics as an AI focus area in 2025.[1]
  • 32% of surveyed pharma and medtech leaders had taken steps to scale generative AI by late summer 2024.[2]
  • 44% of life-sciences organizations used AI in medical affairs and physician engagement in 2026.[3]
  • 80% of pharma and biotech respondents identified data analytics and data science as an AI focus area in 2025.[1]
  • 74% of pharma and biotech respondents were actively using AI in 2025.[1]
  • 53% of pharma and biotech respondents identified agentic AI as an AI focus area in 2025.[1]

Automation in the lifescience industry

  • 44% of life-sciences organizations reported limited maturity in funding, supporting or scaling AI and automation in 2026.[3]
  • 21% of life-sciences leaders were piloting robotic process automation in 2023.[4]
  • 36% of life-sciences leaders were scaling robotic process automation adoption in 2023.[4]
  • 32% of life-sciences leaders used robotic process automation as a way of life in 2023.[4]
  • 87% of life-sciences organizations indicated that AI agents were being integrated into workflows, products or services in 2026.[3]
  • 56% of global life-sciences respondents ranked automation among their top digital-transformation opportunities for the next two years in 2024.[5]

Digital Transformation in the pharmaceuticals and biotech sector (sector benchmark)

  • 58.1% of global pharmaceutical-industry survey respondents were in the pilots or systematic-ongoing-actions stages of Pharma 4.0 adoption in 2023.[6]
  • 35% of clinical-research organizations surveyed were piloting digital technologies in 2024, up from 29% in 2019.[7]
  • 13% of clinical-research organizations surveyed reported a comprehensive AI-driven digital programme in 2024.[7]
  • 15.1% of global pharmaceutical-industry survey respondents reported that Pharma 4.0 digital transformation had not started in 2023.[6]
  • 45% of pharmaceutical companies surveyed were pursuing digitalization as an innovation or technology in 2024.[8]

Technology Adoption in the pharmaceuticals and biotech sector (sector benchmark)

  • 70% of global biopharma respondents had adopted an R&D data platform in 2023.[9]
  • 37% of small biopharma respondents reported that more than 60% of their R&D laboratory instruments had automated data capture in 2024.[10]
  • 59% of global biopharma respondents had adopted artificial intelligence or machine learning in 2023.[9]
  • 63% of global biopharma respondents had adopted robotics and automation in 2023.[9]
  • 55% of biopharma AI adopters reported using AI in process development in 2024.[11]

Cloud Computing in the pharmaceuticals and biotech sector (sector benchmark)

  • 49% of biopharma survey respondents reported using cloud computing to facilitate day-to-day work in 2021.[12]
  • 77% of life-sciences commercial IT leaders reported investing primarily in cloud infrastructure in 2024.[13]
  • 18% of global biopharma respondents had adopted cloud-based scientific software or SaaS in 2023.[9]
  • 17% of large biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[11]
  • 23% of small biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[11]

Big Data in the pharmaceuticals and biotech sector (sector benchmark)

  • 55% of large pharmaceutical companies surveyed were pursuing big data and analytics in 2024.[8]
  • 33% of biopharma survey respondents reported using data lakes in day-to-day operations in 2021.[12]
  • 49% of clinical-research survey respondents reported using AI and big-data analytics in drug development in 2024.[7]

05 Statistics

Data & Analytics

Data readiness remains a gating item for scaling AI: 96% of biopharma leaders said data was not ready for AI in 2025.

Business intelligence in the lifescience industry

  • 14% of life sciences companies in the United States and Europe were extremely confident in their data insights in 2023.[14]
  • 91% of life sciences competitive-intelligence leaders expected their function’s strategic importance to hold steady or grow over the next five years in 2026.[15]
  • 50% of multinational pharmaceutical, biotechnology and life sciences executives reported tangible value from market-sensing product strategies in 2025.[16]
  • About 50% of life sciences survey participants said accessing business-unit-specific data insights was a significant or very significant challenge in 2023.[14]
  • 4 data sources and 4 consultants were used on average for each life sciences data project in 2023.[14]
  • Dashboards were the most frequently used method for communicating value and tracking medical-affairs interactions and insights in 2024.[17]

Data analytics in the lifescience industry

  • 96% of biopharma leaders said their data was not ready for artificial intelligence in 2025.[18]
  • 23% of small biopharma companies and 17% of large biopharma companies had adopted cloud-based scientific software or SaaS in 2024.[11]
  • 48% of pharmaceutical companies used big data and analytics in 2024, including 55% of large companies and 43% of small and midsize companies.[8]
  • 55% of biopharma AI adopters had applied AI in process development in 2024.[11]
  • 17% of small biopharma companies and 46% of large biopharma companies said they could attract and hire skilled AI talent in 2024.[11]
  • 25% of large biopharma respondents reported foundational AI readiness in 2024, compared with 9% of small biopharma respondents.[11]

Data Quality in the pharmaceuticals and biotech sector (sector benchmark)

  • Across 125 senior U.S. life-sciences leaders, 81% said accuracy and confidence in data were critical components of AI success in biopharma in 2026.[19]
  • Across 500 pharmaceutical and biotechnology executives globally, 44% said their organization was prepared on data quality and completeness in 2025.[20]
  • Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 73% reported significant data quality issues in 2025.[19]
  • Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 96% said their data was not well-structured or AI-ready for scaling in 2025.[19]
  • Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 81% identified data quality as their top data issue for the next 12 months in 2025.[19]

Data Governance in the pharmaceuticals and biotech sector (sector benchmark)

  • Across 500 pharmaceutical and biotechnology executives globally, 54% said their organization was prepared on data governance in 2025.[20]
  • Across 200 global life-sciences R&D respondents, 46% called for templates for standardization and metadata to make data FAIR at scale in 2024.[21]
  • Across 200 global life-sciences R&D respondents, 51% identified maintenance and management of data standards and ontologies as a key FAIR-data need in 2024.[21]
  • Across 11 pharmaceutical regulatory organizations, 9% reported a comprehensive approach to onboarding standards such as IDMP and XEVMPD, with regular source qualification, connected systems and data cleaning in 2023.[4]
  • Across 200 global life-sciences R&D respondents, 49% called for more data-governance frameworks to make data FAIR at scale in 2024.[21]

KPIs in the lifescience industry

  • 70% of surveyed pharmaceutical companies tracked scientific-response-document access through medical-information websites in 2024.[22]
  • 16% of surveyed pharmaceutical companies captured analytics on internal use of medical-information assets in 2024.[22]
  • 71% of surveyed pharmaceutical companies tracked response turnaround among customer-query metrics in 2024.[22]
  • 47% of surveyed pharmaceutical companies tracked scientific-response-document downloads in 2024.[22]
  • 68% of surveyed pharmaceutical companies tracked customer-satisfaction surveys among customer-query metrics in 2024.[22]
  • 58% of surveyed pharmaceutical companies tracked abandonment rate among customer-query metrics in 2024.[22]

06 Statistics

Strategy & Growth

Venture and alliance activity stays high alongside M&A: global life-sciences venture deals totaled 515 in 2025 at $18 billion.

Growth in the lifescience industry

  • 911 life sciences venture deals were recorded globally in 2023, totaling $24 billion.[12]
  • 72 biotech companies generated more than $500 million in sales in 2025, a record number globally.[23]
  • 515 life sciences venture deals were recorded globally in 2025, with total venture value of $18 billion.[12]
  • $232 billion in revenue was generated by the global biotech industry in 2025, according to EY.[23]
  • $20.6 billion was raised by biotech companies through venture capital in 2025.[23]
  • 948 life sciences venture deals were recorded globally in 2024, totaling $27 billion.[12]

Differentiation in the lifescience industry

  • 51% was the five-year average share of life sciences M&A spending represented by deals valued at $5 billion or more.[23]
  • 164 EMEA healthcare and life sciences R&D partnerships were recorded in 2025, down from 176 in 2024.[24]
  • AI-enabled drug discovery, manufacturing and novel science were identified as three pillars of pharma strategy in data published in 2025.[23]
  • 469 therapeutic-platform and biopharma R&D partnerships were recorded globally in 2024.[24]
  • Over 7,100 clinical trials were listed by China in the WHO International Clinical Trials Registry Platform in 2024.[25]
  • $4.2 billion was the potential value of the Novartis–Shanghai Argo Biopharmaceutical alliance announced in 2024.[23]

Mergers and acquisitions in the lifescience industry

  • Global healthcare and life sciences M&A reached 585 transactions and $269.3 billion in announced value in 2025.[24]
  • 406 life sciences M&A transactions totaling $305 billion were recorded in 2021.[12]
  • Life sciences M&A deal volume fell 12% in 2025 compared with 2024.[23]
  • 198 life sciences M&A transactions totaling $135 billion were recorded in 2022.[12]
  • $1.1 billion was the average life sciences M&A deal size in 2025.[12]
  • $240 billion in life sciences M&A deals were signed in 2025, up 81% in value from 2024.[23]

Strategic partnerships in the lifescience industry

  • 282 biopharma alliance deals were recorded globally in 2021, with $155 billion in potential deal value.[23]
  • 317 biopharma alliance deals were recorded globally in 2019, with $105 billion in potential deal value.[23]
  • 237 biopharma alliance deals were recorded globally in 2022, with $164 billion in potential deal value.[23]
  • RNA- and oligonucleotide-focused deals represented 12% of biopharma partnership transactions in 2024, up from 7% in 2023.[26]
  • 271 biopharma alliance deals were recorded globally in 2017, with $67 billion in potential deal value.[23]
  • 245 biopharma alliance deals were recorded globally in 2024, with $172 billion in potential deal value.[23]

07 Statistics

People & Workforce

Workforce stability and job-market activity are both measurable: U.S. life sciences job postings rose from 597,214 in 2023 to 660,968 in 2024.

Hiring in the lifescience industry

  • 0.8% was the decline in U.S. life sciences employment between August 2023 and August 2024.[27]
  • 597,214 U.S. life sciences job postings were recorded in 2023.[28]
  • 660,968 U.S. life sciences job postings were recorded in 2024.[28]
  • 58% of analyzed R&D professionals who changed roles in 2024 moved to a pharmaceutical company.[2]
  • 68,581 unique U.S. life sciences job postings were published in an average month during 2021–2022.[28]

Employee retention in the lifescience industry

  • 8.5% was Merck’s global overall employee turnover rate in 2020.[29]
  • Most North American life sciences companies surveyed reported average employee tenures of three to five years in 2025.[30]
  • 84% of North American life sciences companies surveyed reported voluntary turnover below 10% in 2025.[30]
  • 8.5% was Merck’s global voluntary employee turnover rate in 2022.[29]
  • 11.1% was Merck’s global overall employee turnover rate in 2021.[29]

Remote Work in the pharmaceuticals and biotech sector (sector benchmark)

  • Among privately held life-sciences companies surveyed, 21.7% had some portion of their workforce fully remote in 2025.[31]
  • Among life-sciences companies with remote-work options, 50.0% cited competition with technology and other industries as a reason for their policy in 2023.[32]
  • Across U.S. chemical and pharmaceutical manufacturers, 5.7% of positions were fully remote in the 2024 hiring outlook survey.[33]
  • Across U.S. life sciences companies, 65.9% reported implementing, expanding, or considering remote-work options for at least some employees in 2023.[32]

Hybrid Work in the pharmaceuticals and biotech sector (sector benchmark)

  • Across U.S. chemical and pharmaceutical manufacturers, 44.5% of positions were fully hybrid in the 2024 hiring outlook survey.[33]
  • Among surveyed life-sciences employers in the BioHealth Capital Region, 60% expected at least a hybrid workforce after the pandemic in 2021.[34]
  • Among life-sciences CEOs, 83% expected corporate employees whose roles were traditionally office-based to work in a hybrid environment three years after the 2024 survey.[3]
  • Among surveyed life-sciences companies in the MassBio Human Resources Roundtable, 97% planned to implement hybrid work models for the long term in 2022.[35]

Upskilling in the lifescience industry

  • 32% of surveyed life sciences employees said their organization prioritized training recognized externally or adding meaningful resume value.[36]
  • 15% was the growth in the overall life sciences R&D talent pool from 2023 to 2024.[2]
  • 10% of surveyed U.S. life sciences professionals received a pay increase after undertaking AI skills training.[37]
  • 47% of life sciences employees said technical upskilling was an available organizational training format.[36]
  • 26% was the growth in the availability of AI skills among life sciences R&D professionals from 2023 to 2024.[2]

Employee Engagement in the pharmaceuticals and biotech sector (sector benchmark)

  • Across the Culture Amp pharmaceuticals benchmark, 17% of employees disagreed that they had seen positive changes based on recent employee survey results in July 2026.[38]
  • Across the Culture Amp pharmaceuticals benchmark, 91% of employees agreed they understood how their work contributed to company goals in July 2026.[38]
  • Across the Culture Amp pharmaceuticals benchmark, 18% of employees were thinking of or actively seeking another job in July 2026.[38]
  • At Amneal Pharmaceuticals, global employee engagement reached 88% in the company’s 2024 reporting year.[39]

DEI in the lifescience industry

  • 17 percentage points was the decline between 2024 and 2022 in life sciences professionals identifying diversity as important when considering new employment.[40]
  • 48% of GSK’s global employees were women at the end of 2024.[41]
  • 68% of surveyed life sciences professionals said diversity was important when considering new employment in 2024.[40]

08 Statistics

Customer & Sales

Customer experience in the lifescience industry

  • 86% of surveyed oncology key opinion leaders were satisfied or very satisfied with biopharma engagement in 2024.[19]
  • 94% of surveyed oncology key opinion leaders said scientific exchange between clinical experts and pharmaceutical companies was becoming more important in 2024.[19]
  • 40% of healthcare professionals were still developing their digital affinity in DT Consulting’s 2024 life-sciences research.[42]
  • 58 out of 100 was pharma’s global Customer Experience Quotient score in DT Consulting’s 2024 research.[42]
  • 28% of healthcare professionals said pharmaceutical customer-engagement strategies met their needs effectively in a 2025 global survey.[12]

Customer retention in the lifescience industry

  • 94% of targeted U.S. cardiologists used CRM Engage to communicate with life-sciences field teams in June 2023.[19]
  • 61% of targeted U.S. family-medicine prescribers used CRM Engage to communicate with life-sciences field teams in June 2023.[19]
  • 32% of surveyed oncology key opinion leaders said their satisfaction with biopharma engagement varied substantially across companies in 2024.[19]
  • 72% of surveyed oncology key opinion leaders interacted with medical and sales field teams in 2024.[19]
  • 44% of surveyed oncology key opinion leaders reported a lack of coordination or alignment across biopharma functions in 2024.[19]

Customer acquisition in the lifescience industry

  • 36% of healthcare professionals reported engaging with pharmaceutical or healthcare-industry representatives by telephone in an IQVIA survey.[43]
  • 82% of healthcare professionals said digital healthcare-industry content prompted them to want to learn more at least some of the time.[43]
  • 72% of healthcare professionals said informational emails were more convenient than in-person visits in IQVIA research.[43]
  • 73% of healthcare professionals preferred virtual product-topic details covering efficacy, safety or affordability in IQVIA research.[43]
  • 66% of healthcare professionals preferred in-person visits when interacting with pharmaceutical representatives and medical science liaisons in IQVIA research.[43]

Customer loyalty in the lifescience industry

  • 77% of healthcare professionals valued a trusted source or provider when using a pharmaceutical website in research cited by EMJ Reviews.[44]
  • 79% of healthcare professionals valued up-to-date information when using a pharmaceutical website in research cited by EMJ Reviews.[44]
  • 67 was the Customer Experience Quotient score for face-to-face medical-representative meetings in DT Consulting’s 2024 research.[7]
  • 30 out of 100 was pharma’s overall Customer Experience Quotient score for patient interactions in DT Consulting research cited by Indegene.[42]
  • 91% of healthcare professionals wanted pharmaceutical companies to contact them before a congress in research cited by EMJ Reviews.[44]

Lead generation in the lifescience industry

  • 88% of life-sciences field representatives used digital channels to reach and engage healthcare professionals in Veeva’s 2020 North American survey.[19]
  • 85% of pharmaceutical respondents were interested or very interested in generative AI for consumer marketing and patient support in a 2024 survey.[45]
  • 61% of pharmaceutical marketers were very interested in innovative sales-and-marketing integration in a 2024 survey.[45]
  • 75% of large pharmaceutical companies using dynamic targeting refreshed targeting monthly in Axtria’s 2024 benchmarking study.[46]
  • 64% of pharmaceutical marketers were very interested in healthcare-professional omnichannel marketing in a 2024 survey.[45]

09 Statistics

Marketing & Brand

Marketing programs show quantified capability gaps and spending pressure, including a 4.8% five-year compound annual growth rate of pharmaceutical advertising expense through 2024.

Marketing in the lifescience industry

  • 63% of life-science drug-development-services companies tracked marketing return on investment in 2024.[47]
  • 81% of life-science drug-development-services companies developed an annual marketing plan in 2024.[47]
  • 40% of life-science drug-development-services companies developed an annual public-relations or communications plan in 2024.[47]
  • 81% of life-science drug-development-services companies had a clearly defined value proposition in marketing collateral in 2024.[47]
  • 4.8% was the five-year compound annual growth rate of pharmaceutical advertising expense through 2024.[48]

Digital marketing in the lifescience industry

  • 37% was the pharmaceutical industry’s digital-strategy capability score in 2023.[49]
  • 26% was the pharmaceutical industry’s online-advertising capability score in 2023.[49]
  • 31% was the pharmaceutical industry’s search-engine-optimization capability score in 2023.[49]
  • 38% was the pharmaceutical industry’s website-usability capability score in 2023.[49]
  • 31% was the pharmaceutical industry’s e-commerce digital capability score in 2023.[49]

Branding in the lifescience industry

  • $822 million was Yunnan Baiyao’s pharmaceutical brand value in 2024.[50]
  • $5.9 billion was Lilly’s pharmaceutical brand value in 2024.[50]
  • $4.4 billion was Sanofi’s pharmaceutical brand value in 2024.[50]
  • $13.4 billion was Johnson & Johnson’s pharmaceutical brand value in 2024, making it the world’s most valuable pharma brand.[50]
  • $5.1 billion was Novo Nordisk’s pharmaceutical brand value in 2024.[50]

Social media in the lifescience industry

  • 13% was the average use of Instagram by the pharmaceutical companies studied worldwide in 2024.[51]
  • 12% was the average use of Facebook by the pharmaceutical companies studied worldwide in 2024.[51]
  • 9% was the average use of X by the pharmaceutical companies studied worldwide in 2024.[51]
  • 17% was the average use across social channels by the pharmaceutical companies studied worldwide in 2024.[51]
  • 1% was the average use of TikTok by the pharmaceutical companies studied worldwide in 2024.[51]

Influencer Marketing in the pharmaceuticals and biotech sector (sector benchmark)

  • 29% of healthcare and pharmaceutical marketers reported dedicated but flat budgets for creator or influencer marketing in 2026, globally.[52]
  • 44% of physicians in Europe, APAC and North America said healthcare influencer or KOL content had changed their perception of a medication in 2024.[53]
  • 50% of physicians in Europe, APAC and North America said healthcare influencer or KOL content had changed their prescribing choices in 2024.[53]
  • 4.5% of high-engagement prescription-drug promotion posts across Facebook, Instagram, TikTok and YouTube came from pharmaceutical companies in the United States in 2025.[54]
  • 10% of healthcare and pharmaceutical marketers said they did not invest in creator or influencer marketing in 2026, globally.[52]

10 Statistics

Operations & Execution

Manufacturing and quality signals show execution risk: 98 drug shortages were identified in the United States in 2024.

Process optimization in the lifescience industry

  • 5% manufacturing-productivity decline was reported for biopharma after 2018, while unit costs largely plateaued through 2026.[2]
  • 25% productivity growth and more than 50% unit-cost reduction were achieved in biopharma manufacturing between 2014 and 2018.[2]
  • 76.08% was Star Combo Pharma’s production OEE in FY2024, up from 75.00% in FY2023.[55]
  • 40% of biopharma executives said cost-cutting compromises product quality in 2025.[56]
  • 36% of biopharma executives said manufacturing-process modifications were driven more by cost control than quality improvement in 2025.[56]

Operational efficiency in the lifescience industry

  • 1.07 was the revenue-weighted industrial-productivity score for life sciences in 2025.[57]
  • 335 batches were manufactured by Star Combo Pharma in FY2024.[55]
  • 78,489 potential production hours were available at Star Combo Pharma in FY2024.[55]
  • 1.13 was the 2025 productivity score for animal-health companies in the LNS Research life-sciences peer group.[57]
  • 0.94 was the 2025 productivity score for nutraceutical companies in the LNS Research life-sciences peer group.[57]

Quality management in the lifescience industry

  • 4 Class 3 recalls of centrally authorised medicines occurred in the European Union in 2024.[58]
  • 395 suspected quality-defect notifications were received by the European Medicines Agency in 2024.[58]
  • 100 pharmaceutical-product recalls were attributed to cGMP deviations in FY2024.[59]
  • 221 confirmed quality defects led to batch recalls of nine centrally authorised medicines in the European Union in 2024.[58]
  • 30 pharmaceutical-product recalls were attributed to labeling problems in FY2024.[59]

Supply chain in the lifescience industry

  • 19% was the 2024 increase in the average price of generic injectable medicines in the United States.[60]
  • 98 drug shortages were identified in the United States by the USP Medicine Supply Map in 2024.[61]
  • Approximately 5% of UK medicine-supply notifications in 2024 were attributed to logistics, including storage and transportation.[62]
  • 100% of new injectable shortages in 2024 were predicted as high risk before occurrence by the USP Medicine Supply Map.[60]
  • 89% of drug shortages identified in 2024 had carried over from 2023.[61]

Outsourcing / Offshoring in the pharmaceuticals and biotech sector (sector benchmark)

  • 54% of global biotech and pharma companies outsourced regulatory activities in 2024, according to an IQVIA industry report.[43]
  • 67% of global biotech and pharma companies outsourced pharmacovigilance operations in 2024, according to an IQVIA industry report.[43]
  • 41% of surveyed pharmaceutical and biotech R&D leaders increased their use of functional-service-provider outsourcing versus two years earlier in 2023.[8]
  • 12% of total API volume used in the United States was produced domestically in 2024, with most supply coming from India and the European Union.[63]
  • 74% of surveyed pharmaceutical and biotech R&D leaders ranked patient recruitment among the top five drug-development activities likely to be outsourced in 2023.[8]

11 Statistics

Finance & Pricing

Pricing and discounts heavily shape net outcomes, with U.S. net drug spending at $650 billion in 2023 after discounts.

Pricing strategy in the lifescience industry

  • 47% of drugs launched in 2020–2021 had annual launch prices above $150,000, compared with 9% of drugs launched in 2008–2013.[64]
  • 20%–50% or more is the estimated discount from list prices available through the U.S. 340B drug-pricing program.[22]
  • $650 billion was U.S. net drug spending in 2023 after discounts, compared with a higher undiscounted list-price total.[65]
  • $536 billion in total discounts were provided to the U.S. medicines market in 2024, nearly matching the market’s $544 billion list-price value in 2015.[43]
  • $27 billion was the 2024 U.S. net-revenue contribution from specialty medicines, driven largely by oncology and immunology products.[43]

Cost reduction in the lifescience industry

  • CHF1.161 billion was Roche Pharmaceuticals’ restructuring cost in 2024, focused on R&D optimization, manufacturing-network strategy and process simplification.[66]
  • 45% of commercial AI value was categorized as cost reduction, with the remainder categorized as revenue uplift, in Deloitte’s life-sciences analysis.[12]
  • 6%–12% of revenue is the estimated cost-efficiency opportunity for medtech companies deploying generative AI and related technologies.[12]
  • $1.4 billion is the estimated maximum annual cost saving for a large medtech company applying AI to supply-chain and manufacturing activities.[12]
  • DKK8 billion was Novo Nordisk’s targeted annual saving from its 2025 workforce and organizational streamlining program by the end of 2026.[67]

Profitability in the lifescience industry

  • 17.8% was Bristol Myers Squibb’s reported operating margin in 2024.[68]
  • 20.0% was the average net-income margin of U.S. pharmaceutical manufacturers in 2017.[69]
  • 21.4% was the average net-income margin of U.S. pharmaceutical manufacturers in 2023.[69]
  • 24.8% was the average net-income margin of U.S. pharmaceutical manufacturers in 2022.[69]
  • 23.2% was the average annual net-income margin of U.S. pharmaceutical manufacturers from 2017 through 2024.[69]

Financial planning in the lifescience industry

  • 73% was the increase in large-pharma R&D expenditure from 2019 to 2024.[70]
  • $49.5 billion was U.S. business expenditure on pharmaceutical R&D in 2022, approximately two-thirds of the OECD total shown.[71]
  • 4.4% was the average annual growth rate of EU pharmaceutical R&D spending from 2010 to 2022.[72]
  • $23.4 billion was China’s business expenditure on pharmaceutical R&D in 2022, up 365% from 2010 in constant 2015 purchasing-power-parity dollars.[71]
  • 22.3 months was the median cash runway for emerging biotech companies in the third quarter of 2024.[73]

12 Statistics

Product & Service

Clinical and product pipeline throughput remains central, with 5,488 industry-sponsored phase I-to-III clinical trials recorded globally by November 2024.

Product development in the lifescience industry

  • Fewer than 10% of compounds entering development reached the market, according to the 1991–2020 analysis.[43]
  • 44% of European pharmaceutical research and development spending went to clinical trials in 2024.[72]
  • 43 new chemical and biological entities originated in Japan during 2019–2023.[72]
  • 5,488 industry-sponsored phase I-to-III clinical trials were recorded globally by November 2024.[72]
  • 71 new chemical and biological entities originated in China during 2019–2023.[72]

Product lifecycle in the lifescience industry

  • 65% of branded medicine net revenue had been generated by the time a product was nine years old.[43]
  • 55 late-life novel-active-substance indication combinations were identified in the 190-combination study.[43]
  • 19 medicines exceeded the inflation-adjusted blockbuster threshold in 2000.[43]
  • 45% of late-life indication combinations represented the first new treatment for their condition in more than five years.[43]
  • Oncology, immunology and diabetes products represented 5% of blockbusters in 2000.[43]

After-sales in the lifescience industry

  • Over 30,000 technicians were represented in Aquant’s general medical-device service dataset.[74]
  • Patient-support programs involved 10 to 20 vendors per program in the cited industry analysis.[43]
  • More than $5 billion was invested annually by pharmaceutical companies in patient support programs in 2025.[43]
  • More than 5 million service events covered over 600,000 laboratory-equipment assets in Aquant’s dataset.[74]
  • Nearly 2 million imaging service events covered nearly 300,000 assets in Aquant’s dataset.[74]

Value proposition in the lifescience industry

  • Oncology medicines had a 25% positive-return rate in the analyzed launch cohorts.[43]
  • Orphan medicines had a 16% positive-return rate in the analyzed launch cohorts.[43]
  • Roughly three-quarters of lifetime revenue was generated by 174 medicines in the IQVIA analysis.[43]
  • Antibacterial medicines had an 18% positive-return rate in the analyzed launch cohorts.[43]
  • Medicines accounted for 20% to 60% of health spending in developing countries.[75]

13 Statistics

Sustainability & Ethics

Reporting and assurance concerns remain prominent, with 87% of surveyed investors believing corporate sustainability reporting contains unsupported claims.

Sustainability in the lifescience industry

  • 66% of pharmaceutical companies publicly disclosed ESG and sustainability performance data, according to an industry reporting review.[76]
  • 73% of life sciences and health-care organizations slightly increased sustainability investments in 2024, globally.[12]
  • More than 50% of surveyed life sciences and pharmaceutical executives said their organizations were completely ready for sustainability reporting requirements in 2025.[77]
  • 49% of surveyed life sciences and pharmaceutical organizations reported circular-economy topics in their ESG reporting.[77]
  • 39% of life sciences and health-care organizations ranked climate change among their top three issues for the following year in 2024, globally.[12]

ESG in the lifescience industry

  • 87% of surveyed investors believed corporate sustainability reporting contained unsupported claims in the pharmaceutical-reporting study.[76]
  • 32% of life sciences and health-care respondents reported significant progress toward ESG goals in 2024.[12]
  • 53% of surveyed life sciences and pharmaceutical organizations included climate and carbon emissions in ESG reporting.[77]
  • 75% of surveyed investors said independent reasonable assurance would increase confidence in sustainability reporting.[76]
  • 58% of surveyed life sciences and pharmaceutical organizations included responsible supply chains in ESG reporting.[77]

Ethics in the lifescience industry

  • 82% of surveyed biopharmaceutical industry associations said their codes aligned with the APEC Mexico City Principles in 2020.[78]
  • 15% of surveyed biopharmaceutical industry associations reported challenges aligning with the APEC Mexico City Principles in 2020.[78]
  • 40% of surveyed biopharmaceutical industry associations planned code amendments within the following year in 2020.[78]
  • 87% of surveyed biopharmaceutical industry associations were considering updating their ethics codes within five years of 2020.[78]
  • 65% of surveyed biopharmaceutical industry associations offered ethics training to members in 2019.[78]

CSR in the lifescience industry

  • 6.37 out of 10 was the patient preference score for pharmaceutical CSR focused on promoting public health in Korea.[79]
  • Fewer than 50% of Boston-area life sciences companies responding to the inclusion pledge survey reported progress on it.[25]
  • 25% of health-sector emissions were linked to pharmaceutical and other medical goods, representing a major social-responsibility issue for the industry in OECD countries in 2018.[71]
  • 6.35 out of 10 was the patient preference score for pharmaceutical emergency-disaster-relief CSR in Korea.[79]
  • 87% of investors in a pharmaceutical ESG-reporting survey believed corporate reporting contained unsupported sustainability claims.[76]

Circular economy in the lifescience industry

  • 294.07 thousand metric tons of Bayer waste was directed to disposal in 2025.[80]
  • 32.6% was Chugai’s corrected waste-recycling rate in 2023 after revising its calculation criteria.[81]
  • More than 60% of surveyed biopharmaceutical manufacturers used incineration as the main disposal method for single-use assemblies.[6]
  • Less than 15% of surveyed biopharmaceutical manufacturers used chemical or mechanical recycling for single-use technology waste.[6]
  • 44.7% of Bayer’s total waste was nonrecycled waste in 2025.[80]

Carbon footprint in the lifescience industry

  • 70% of active pharmaceutical ingredients were estimated to be small molecules synthesized from crude oil and natural gas.[2]
  • Less than 20% of surveyed API manufacturers had detailed decarbonization implementation plans in 2023.[2]
  • 49 tons of carbon-dioxide equivalent were produced per 1 million dollars of pharmaceutical-industry revenue in 2019.[82]
  • 4.4% of global carbon emissions were attributed to health care in the reviewed pharmaceutical carbon-footprint literature in 2023.[82]
  • Nearly 70% carbon-emissions reduction was associated with continuous rather than batch pharmaceutical manufacturing in a literature review.[82]

15 Statistics

Globalization & Expansion

Regional sales concentration is substantial, with North America accounting for 51% of global drug sales in 2024.

Globalization in the lifescience industry

  • €55 billion was invested in European pharmaceutical research and development in 2024.[72]
  • 51.8% of global pharmaceutical sales came from the United States in 2024.[93]
  • 130,000 people were employed in pharmaceutical research and development in Europe in 2024.[72]
  • 51% of global drug sales were generated in the United States in 2024.[23]
  • 45% of new pharmaceutical products originated in the United States in 2024.[23]

Supplier management in the lifescience industry

  • 60% of active pharmaceutical ingredients were produced in China according to a 2023 life-sciences supply-chain risk report.[5]
  • 11% was the compound annual growth rate of Chinese pharmaceutical manufacturing investment from 2018 to 2022.[72]
  • 15% was the compound annual growth rate of European pharmaceutical manufacturing investment from 2018 to 2022.[72]
  • 1st was the ranking of supply-chain or distribution failure among life-sciences risks in 2025.[94]
  • 60% of surveyed biopharma organizations were assessing supplier-concentration risk in 2023.[12]

Stakeholder management in the lifescience industry

  • 24% of healthcare professionals preferred requesting information through social media in 2023.[43]
  • 113 low- and middle-income countries were covered by the 2024 Access to Medicine Index.[95]
  • 19% of healthcare professionals preferred requesting information through a live-chat help desk in 2023.[43]
  • 20% was the weighting of Product Delivery in the 2024 Access to Medicine Index.[95]
  • 15% was the weighting of Governance of Access in the 2024 Access to Medicine Index.[95]

Distribution channels in the lifescience industry

  • 25 or more engagement channels were measured by IQVIA ChannelDynamics.[43]
  • 48,000 manufacturers were represented in IQVIA ChannelDynamics data.[43]
  • 32% was the increase in email send rates achieved in an IQVIA omnichannel case study.[43]
  • 20% was the increase in new-patient initiation for one brand in an IQVIA Next Best Action case study.[43]
  • 70% of healthcare professionals preferred interacting with representatives and medical-science liaisons in person in 2023.[96]

Key questions about the lifescience industry

How big is the life-sciences market in 2024?
Global prescription pharmaceutical sales reached $1.53 trillion in 2024, with global ex-factory value €1.414 trillion (=$1.529 trillion).
What pace of growth should buyers plan for through 2029?
IQVIA forecasts global medicine spending growth at a 5–8% CAGR through 2029 to about $2.4 trillion.
Which companies lead the lifescience industry?
Eli Lilly leads Gitnux's 2026 lifescience ranking with an Overall score of 9.6, with R&D at 20.5% of revenue and operating margin at 40.4%. Novo Nordisk is the highest-ranked pharmaceutical company at 9.1, with operating margin at 41.3% and R&D at 16.8% of revenue.
What technology shifts are most visible in 2024–2026?
Automation and data analytics show broad uptake, and 87% of life-sciences organizations indicated AI agents integrated into workflows, products, or services in 2026.
How concentrated is demand geographically?
North America held 54.8% of global pharmaceutical sales in 2024, versus 22.7% for Europe, 7.1% for China, and 4.0% for Japan.
What regulatory output sets expectations for new launches?
The FDA approved 46 novel drugs in 2025; 39 (85%) were approved during the first review cycle.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 10). Lifescience Industry Statistics. Gitnux. https://gitnux.org/lifescience-industry-statistics
MLA
Samuel Norberg. "Lifescience Industry Statistics." Gitnux, 10 Nov 2026, https://gitnux.org/lifescience-industry-statistics.
Chicago
Samuel Norberg. 2026. "Lifescience Industry Statistics." Gitnux. https://gitnux.org/lifescience-industry-statistics.

Sources & references

108 sources cited across this report

  1. nvidia.com
  2. mckinsey.com
  3. assets.kpmg.com
  4. resources.indegene.com
  5. wtwco.com
  6. ispe.org
  7. pmlive.com
  8. ppd.com
  9. techresearchinfo.com
  10. benchling.com
  11. test.benchling.com
  12. deloitte.com
  13. insights.indegene.com
  14. komodohealth.com
  15. sedulogroup.com
  16. zs.com
  17. medicalaffairs.org
  18. pharmalive.com
  19. veeva.com
  20. capgemini.com
  21. pistoiaalliance.org
  22. pmc.ncbi.nlm.nih.gov
  23. ey.com
  24. dealforma.com
  25. axios.com
  26. williamblair.com
  27. cbre.ae
  28. bioutah.org
  29. merck.com
  30. leap-hr-lifesciences-searchlight.com
  31. jthelander.com
  32. innovatebio.org
  33. naceweb.org
  34. biobuzz.io
  35. massbio.org
  36. cognizant.com
  37. hub.epmscientific.com
  38. cultureamp.com
  39. amneal.com
  40. biospace.com
  41. sec.gov
  42. indegene.com
  43. iqvia.com
  44. emjreviews.com
  45. digitalhealthcoalition.org
  46. axtria.com
  47. scorrmarketing.com
  48. wpp.com
  49. target-internet.s3.eu-west-2.amazonaws.com
  50. brandfinance.com
  51. s3.amazonaws.com
  52. brand-news.it
  53. sermo.com
  54. jamanetwork.com
  55. investors.starcombo.com.au
  56. cdn.cytivalifesciences.com
  57. lnsresearch.com
  58. ema.europa.eu
  59. fda.gov
  60. eco-cdn.iqpc.com
  61. usp.org
  62. gov.uk
  63. richmondfed.org
  64. bipartisanpolicy.org
  65. doi.org
  66. financialfilings.com
  67. apnews.com
  68. news.bms.com
  69. csrxp.org
  70. makingpharmaindustry.it
  71. oecd.org
  72. efpia.eu
  73. corporatefinance.kpmg.com
  74. 21176235.fs1.hubspotusercontent-na1.net
  75. who.int
  76. sgs.com
  77. forvismazars.com
  78. apec.org
  79. journals.plos.org
  80. reports.bayer.com
  81. chugai-pharm.co.jp
  82. ispor.org
  83. acrohealth.org
  84. middlemarketcenter.org
  85. lifesciencesny.org
  86. fortinet.com
  87. cpl.thalesgroup.com
  88. kiteworks.com
  89. openpharma.blog
  90. etla.fi
  91. insights.economistenterprise.com
  92. assets.fenwick.com
  93. astrazeneca.com
  94. aon.com
  95. accesstomedicinefoundation.org
  96. test-www.iqvia.com
  97. trade.gov
  98. bio.org
  99. lilly.com
  100. annualreport.novonordisk.com
  101. roche.com
  102. novartis.com
  103. amgen.com
  104. investorrelations.medtronic.com
  105. sanofi.com
  106. corporate.thermofisher.com
  107. news.abbvie.com
  108. pubmed.ncbi.nlm.nih.gov